Bibliographic Info
GuidelineWHO consolidated guidelines on drug-resistant tuberculosis treatment
Year of Publication2019
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
Moderate
Linezolid should be included in the treatment of multidrug-resistant TB or isoniazid-resistant, rifampicin-resistant TB patients on longer regimens
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year2022
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization